Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Spotify Technology (SPOT) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade
Spotify TechnologyTrade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs Spotify Technology — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.83 (market cap $29.60B), while Spotify Technology trades at $484.44 (market cap $103.00B). The key difference: Spotify Technology is far larger — about 3.5× Alnylam Pharmaceuticals, Inc.'s market cap, and Spotify Technology is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.

ALNYSPOT
Market Cap
$29.60B$103.00B
Sector
HealthMedia
52-Week High
$491.22$738.53
52-Week Low
$205.48$412.75
Enterprise Value
$27.56B$92.70B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alnylam Pharmaceuticals, Inc.

ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.

The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.

Spotify Technology

Spotify (SPOT) trades at $489.65, down 4.33% in the last session, amid mixed technical signals and strong fundamentals. The stock shows a bullish moving average trend but neutral oscillators, with key support at $487. Financially, revenue grew to $17.19B in 2025 with a net income margin of 12.87%, while recent news highlights initiatives like AI artist labeling to enhance transparency.

Outlook remains positive with a consensus price target of $598.20, implying 22% upside, driven by subscriber growth and margin expansion. Risks include competitive pressures and cost management, but analyst sentiment is bullish with 62% buy ratings, supporting long-term value for investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY

About Spotify Technology

Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.

Read more on SPOT